Meeting
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
Authors
Pengxiang Li
University of Pennsylvania, Philadelphia, PA
Pengxiang Li , Yu-Ning Wong , Jordan Jahnke , Jalpa A. Doshi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4562)
DOI
10.1200/JCO.2016.34.15_suppl.4562
Abstract #
4562
Poster Bd #
184
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2016 Genitourinary Cancers Symposium
Initial compared to deferred cytoreductive nephrectomy for metastatic kidney cancer and its association with improved survival in the targeted therapy era.
First Author: Liam Connor Macleod
Poster
2015 Genitourinary Cancers Symposium
Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
First Author: Daniel Yick Chin Heng
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu